Health Care [ 2/12 ] | Life Sciences Tools & Services [ 14/73 ]
NASDAQ | Common Stock
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The company is headquartered in Cranford, New Jersey.
Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -0.08 Decreased by -311.08% | -0.15 Increased by +46.67% |
| May 15, 25 | -0.11 Decreased by -249.46% | -0.09 Decreased by -22.22% |
| Feb 17, 25 | -0.09 Decreased by -180.54% | -0.06 Decreased by -55.17% |
| Dec 30, 24 | -0.31 Decreased by -1.83 K% | -0.08 Decreased by -282.38% |
| Aug 28, 24 | 0.04 Decreased by -44.59% | - |
| Mar 31, 24 | 0.07 Increased by +8.55% | - |
| Dec 31, 23 | 0.12 Increased by +173.93% | - |
| Sep 30, 23 | 0.02 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -5.37 M Decreased by -12.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -7.74 M Decreased by -59.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -6.66 M Decreased by -40.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -6.81 M Decreased by -131.25 K% | Decreased by N/A% - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.77 M Decreased by -874.44% | Decreased by N/A% - |
| Mar 31, 24 | 0.00 Decreased by N/A% | -4.84 M Decreased by -890.48% | Decreased by N/A% - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -4.73 M Decreased by -1.34 K% | Decreased by N/A% - |
| Sep 30, 23 | N/A Decreased by N/A% | -5.19 K Increased by +39.45% | - - |